Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants

The human angiotensin-converting enzyme 2 acts as the host cell receptor for SARS-CoV-2 and the other members of the Coronaviridae family SARS-CoV-1 and HCoV-NL63. Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Mathieu, Mekkaoui, Leila, Ilca, F. Tudor, Akbar, Zulaikha, Bughda, Reyisa, Lamb, Katarina, Ward, Katarzyna, Parekh, Farhaan, Karattil, Rajeev, Allen, Christopher, Wu, Philip, Baldan, Vania, Mattiuzzo, Giada, Bentley, Emma M., Takeuchi, Yasuhiro, Sillibourne, James, Datta, Preeta, Kinna, Alexander, Pule, Martin, Onuoha, Shimobi C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432736/
https://www.ncbi.nlm.nih.gov/pubmed/34287040
http://dx.doi.org/10.1128/JVI.00685-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432736/
https://www.ncbi.nlm.nih.gov/pubmed/34287040
http://dx.doi.org/10.1128/JVI.00685-21

Ejemplares similares